Armstrong Henry H Associates Inc. Reduces Holdings in Johnson & Johnson $JNJ

Armstrong Henry H Associates Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 0.8% in the third quarter, HoldingsChannel.com reports. The fund owned 327,811 shares of the company’s stock after selling 2,668 shares during the period. Johnson & Johnson comprises about 5.5% of Armstrong Henry H Associates Inc.’s portfolio, making the stock its 4th biggest holding. Armstrong Henry H Associates Inc.’s holdings in Johnson & Johnson were worth $60,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the company. W.H. Cornerstone Investments Inc. increased its position in Johnson & Johnson by 0.7% during the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock worth $1,206,000 after buying an additional 58 shares during the last quarter. YANKCOM Partnership boosted its stake in shares of Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after acquiring an additional 58 shares during the period. Greenup Street Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 3.1% during the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock worth $309,000 after acquiring an additional 60 shares during the last quarter. Ellis Investment Partners LLC raised its stake in Johnson & Johnson by 0.7% in the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after acquiring an additional 62 shares during the period. Finally, Cypress Wealth Services LLC raised its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after acquiring an additional 62 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $214.41 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company has a market cap of $516.58 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The company has a 50 day moving average of $196.61 and a 200-day moving average of $177.85. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.19.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. The Goldman Sachs Group upped their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Barclays upped their price target on shares of Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $208.35.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.